Trial Profile
A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Rubitecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 10 Sep 2005 New trial record.